Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Febrile seizures following measles and varicella vaccines in young children in Australia

Febrile seizures (FS) are common in childhood with incidence peaking in the second year of life when measles and varicella-containing vaccines are administered.

Research

Risk factors and comorbidities for invasive pneumococcal disease in Western Australian Aboriginal and non-Aboriginal people

Australian Aboriginal people have among the highest rates of invasive pneumococcal disease (IPD) worldwide. This paper investigates clinical diagnosis, risk...

News & Events

Rheumatic heart disease remains a major killer in Oceania region

A new study shows that people living in the Oceania region, including Australia, have the highest risk in the world of dying from rheumatic heart disease.

News & Events

Extra whooping cough shot to protect your bub

Toddlers will now get an additional whooping cough vaccine to protect them against the potentially deadly disease.

News & Events

Taking on a common respiratory infection in kids

Mapping when Respiratory Syncytal Virus (RSV) reaches its seasonal peak will assist how future vaccination programs are carried out.

News & Events

Video: Flu vaccine Q&A

It's that time of year again... Flu vaccine time! Watch Dr Chris Blyth answer commonly asked questions in the video below.

Research

Influenza

Influenza (commonly known as the flu) is caused by a highly contagious virus spread mainly through coughing and sneezing. An annual flu vaccination is the most effective way to prevent flu outbreaks.

News & Events

Childhood influenza vaccination rates improves with better access

More children across Australia are being vaccinated against the flu since funding was expanded and access widened under the National Immunisation Program

Research

Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024

Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season. 

Research

Pneumococcal conjugate vaccine primes mucosal immune responses to pneumococcal polysaccharide vaccine booster in Papua New Guinean children

Invasive pneumococcal disease remains a major cause of hospitalization and death in Papua New Guinean (PNG) children. We assessed mucosal IgA and IgG responses in PNG infants vaccinated with pneumococcal conjugate vaccine (PCV) followed by a pneumococcal polysaccharide vaccine (PPV) booster.